Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ...

United Therapeutics (UTHR) shares soared 4.9% in the last trading session to close at $370.74. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

United Therapeutics (UTHR) announced full enrollment of the TETON 1 study evaluating the use of Tyvaso or treprostinil, inhalation solution or ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., January 21, 2025--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that five posters across its ...

This is a recurring post, regularly updated with new information and offers. Although 2024 has ended, there may still be an opportunity to snag the next level of United Premier status for 2025. United ...

The upstart, clinical stage biotech company Viking Therapeutics, Inc. (NASDAQ:VKTX), which is attempting to disrupt their market leadership has also suffered from a protracted hangover ...

However, Wall Street's enthusiasm for Summit Therapeutics appears to be justified. If ivonescimab fulfills its potential, Summit should be worth a lot more within a few years than it is today.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that five posters across its ...

Glox Therapeutics will receive up to £500,000 of the fund to accelerate the development of its novel precision antibiotics, helping to address the growing need for effective treatments to ...